Merck/Eisai Drops Melanoma Program for Keytruda-Lenvima Combo After Phase III Fail

Results from two late-stage trials posted Friday showed Merck’s Keytruda (pembrolizumab), in combination with Eisai’s Lenvima (lenvatinib), failed to boost survival in two difficult-to-treat advanced cancers.